Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.
Medical Degree: Ain Shams University, Cairo, Egypt
Residency: Harbor Hospital Center, Medicine
Fellowship: Roswell Park Cancer Institute, Georgetown University, Oncology: Georgetown University, Bone Marrow Transplantation
Certification: Internal Medicine; Medical Oncology
Biography:
Dr. Badros has extensive clinical experience in
Bone Marrow Transplantation with special interest
in multiple myeloma. He was involved in the
initial trails of thalidomide and has conducted
many clinical trials for treatment of relapsed
and refractory multiple myeloma. Dr. Badros research
has focused on evaluation of immunological approaches
to eradicate residual myeloma cells in the high-risk
setting following autologous stem cell transplantation
using natural killer (NK) and interleukin -2 (IL-2)
activated cells and non-myeloablative allogeneic
donor grafts.
Dr. Badros is involved in the development of
targeted novel therapeutics. He has completed a
gene therapy trial using G-3039 "Bcl-antisense."
He evaluated the use of the proteosome inhibitor
"bortezomib" in the newly diagnosed myeloma
patients and evaluated the effects of bortezomib
on stem cell. Currently, Dr. Badros is evaluating
various combinations of novel therapies in multiple
myeloma such as Lenalidomide and histone deacetylase
inhibitors (SAHA) in relapsed myeloma patients
alone and in combinations with dexamethasone and/or
bortezomib.
Contact Information:
1-800-373-4111 (physicians only)
1-800-492-5538 (patients and general information)
1-410-328-8919 (news media only)
Print this page
Email this page
Twitter
Facebook
YouTube
